A field in oncology has seen major developments and breakthroughs over the past years.
Personalized treatments and diagnostics have changed how patients are managed.
However, less common cancers with smaller patient size carry significant unmet needs.
These diseases comprise over a quarter of all oncological conditions.
Its clinical presentation and biomarker expression may not be well studied.
Needless to say, clinical trials may present understandable challenges.